Cybin is trading at $11.38, up 5.52%, with no verified news explicitly linking the rise to a specific catalyst.

  • An October 22 report recapped the prior day’s investor presentation, including a reiterated Q4 2026 HLP003 Phase 3 readout timeline and plans for an HLP004 Phase 2 study in Q1 2027. It did not attribute a share-price move to those updates.
  • XBI was down 0.30% at the October 21 close, so the available biotech ETF data does not confirm a sector-wide move in the same direction.